Clinical Trials | June 16, 2026
Lilly’s Jaypirca cuts risk of disease progression or death by 45% in landmark trial
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Jaypirca is making waves in the fight against B-cell malignancies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
